SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Send us your Comments

Never Miss a Story

Sign up for email alerts

 

More People & Company Headlines

How will payment reform impact diagnostic services? Vice president of health policy and strategy at Siemens Healthcare tell us how

What does the U.S. health care industry have to do to survive? Tom Spees offers his thoughts

Virtualization of clinical applications The enterprise solutions architect at UnityPoint Health discusses the "big leap."

Focused Ultrasound New Technology for the new paradigm

Choosing capital maintenance and service contracts MD Buyline offers tips on key issues to consider

IMT Device for AMD Patients

Miniature Implantable Telescope May Save Eyesight for AMD Patients

by Becky Jacoby , Reporter
An Implantable Miniature Telescope (IMT), about the size of a pencil eraser, could be an answer for people suffering from severe macular degeneration, a leading cause of blindness affecting more than 10 million Americans.

The device, said to improve vision acuity approximately three lines on an eye chart, has received unanimous recommendation for approval from an FDA advisory panel.

Story Continues Below Advertisement

ENTERPRISE LEVEL INFORMATION SHARING - register for a demo

McKesson Enterprise Medical Imaging Solutions deliver what you need to stay connected and help ensure that patient information is in the right place at the right time and easily accessible by all members of the care team.



The IMT was invented by VisionCare Opthalmic Technologies (VisionCare) company founders Yossi Gross and Isaac Lipshitz. The device is currently in the midst of a two-year, multi-center phase II/III clinical research trial in the United States.

Kathryn Colby, an eye surgeon at the Massachusetts Eye and Ear Infirmary in Boston helped develop the surgical procedure used to implant the device. She said, "This is one of the few options for people with end-stage macular degeneration."

Cataracts, which many AMD patients have, are removed first. Then the telescope is inserted and held in place by surrounding tissue. The IMT is only implanted in one eye so that patients may use the eye with the implant for center-field vision and the untreated eye for peripheral vision.

Because the procedure requires a larger that usual incision, loss of endothelial cells is a concern. Endothelial cells do not regenerate and are used in keeping the cornea transparent. Scientists, however, believe that cell loss stabilizes over time.

Macular degeneration typically affects people 65 and older and eventually results in blindness. The irreversible disease affects the macula, the part of the retina required for visual activity such as reading and recognizing faces. To date, no treatments have been available for the end-stage of the disease, a category covering nearly 70,000 people per year.

The FDA advisory panel news is welcomed by VisionCare. When approved, estimated late 2009, the firm plans to market the device. It has already been approved for use in Europe, but the company plans to launch the product first in the United States.

Allen W. Hill, President/CEO currently runs the privately held company based in California.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED